Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 30;24(18):4416–4428. doi: 10.1158/1078-0432.CCR-17-3649

Figure 3. Exposure to anti-CTLA does not impact TIL persistence.

Figure 3

(A) Assessment of TIL diversity in the infusion product at the clonal level from tumor harvested pre- (yellow) and post-(blue) anti-CTLA4 therapy for 2 patients. The clonal diversity is expressed by the clonal index (1 = a clonal population, a clonal index closer to 0 = a polyclonal population). (B) Venn diagrams depicting the number of clones found only in one of the 2 conditions [pre (yellow) or post (blue)] as well as the number of REP expanded clones found in both pre and post-anti-CTLA4 TIL products combined in the infusion product (2 patients). (C) Separate tracking TIL post-infusion of both pre- (yellow) and post- (blue) anti-CTLA4 therapy product in both patients over time. For each patients, the percentage change in the tumor burden, baseline being “0” and a negative percentage demonstrating a response.